Featured Articles

31. A New Reality In Life Sciences 2/14/2024

    Gain insight from this author's experience with virtual reality (VR) and the specific benefits of VR in scientific contexts.

32. Big Risks Yield Great Rewards In Cell Therapy 2/14/2024

    George White, Cytiva’s GM of Product Management for Cell and Gene Therapy, provides insight into the latest developments and strategies in cell therapy and where this dynamic field is headed.

33. Finding The Talent To Fuel Biopharma Breakthroughs 2/13/2024

    Explore findings from research into talent pool resilience in the biopharmaceutical industry that incorporate survey insights as well as external data to ensure a more accurate overview.

34. Consolidating The Supply Chain For mRNA 2/12/2024

    Learn about the first end-to-end cGMP facility that was developed for mRNA manufacturing to address the shortage of CDMOs and the inadequate and inefficient supply chain options for sourcing GMP mRNA.

35. Getting Genomic Medicines Ready For Prime Time 2/5/2024

    Explore the benefits of building a manufacturing process early, how research into LNPs in nucleic acid therapeutics will contribute to the development of future drugs, and more.

36. Getting CMC Right For Emerging Technologies 12/20/2023

    Establishing a chemistry, manufacturing, and controls strategy that proves a clinical program is tightly controlled and can address risk is critical to avoiding the pitfalls that stall many promising therapeutics.

37. Following The Science To Develop Best-In-Class Cancer Drugs 12/11/2023

    As innovative cancer therapeutics continue to enter the clinical trial pipeline, some developers are shifting their focus toward developing drugs that are safe and efficacious with minimal toxicity.

38. A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments 12/11/2023

    No two journeys through the drug pipeline are the same; the ability to leverage a variety of approaches for different products is what sets one lean biotech company apart.

39. A Tale Of Two Brothers: The Abpro Founders 12/11/2023

    By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.

40. Welcoming The "Era Of ADCs" 12/5/2023

    Dr. Loretta Itri sat down to explore the promise of TRODELVY®️ and other antibody-drug conjugates as transformative treatments for a range of malignancies and intractable diseases.